| |
|
|
Session 63
Poster Presentations Relationships between Drug Levels and Their Effects Wednesday 1:30 - 3:30 pm Hall A |
| 525 | Lopinavir Drug Levels Predict the Virological and Immunological Outcome as well as Lipid Elevations D. González de Requena*, O. Gallego, F. Blanco, L. Valer, T. Garcia-Benayas, C. De Mendoza, I. Jimenez-Nacher, V. Soriano Hosp Carlos III, Madrid, Spain |
| 526 | Relation between Lopinavir Plasma Blood Concentrations and Hypertriglyceridemia in Naďve and Protease Inhibitors-experienced Patients A. Calboreanu1, J. Dimet2, J.M. Treluyer2, S. Abad1, L. Pecqueux1, A. Krivine2, D. Sicard1, D. Salmon-Ceron*1 1Internal Med Dept, Cochin Hosp, Paris, France and 2Cochin Hosp, Paris, France |
| 527 | Population Pharmacokinetics of Lopinavir/Ritonavir in Experienced Patients B. Best*1, R. Haubrich1, C. Miller1, M. Witt2, C. Kemper3, K. Squires4, C. Diamond5, P. Heseltine6, N. Hellmann7, J. A. McCutchan1, E. Capparelli1, California Collaborative Treatment Group8 1Univ of California at San Diego; 2Harbor-UCLA, Torrance, CA; 3Santa Clara Valley Med Ctr, San Jose, CA; 4Univ of Southern California at Los Angeles; 5Univ of California-Irvine, CA; 6Quest Diagnostics, San Juan Capistrano, CA; 7ViroLogic, San Francisco, CA; and 8Campus California Teacher Group, Etna, CA |
| 528 | Correlation of Viral Load Reduction and Plasma Levels in Multiple Protease Inhibitor Experienced Patients Taking Tipranavir/Ritonavir in a Phase IIB Trial: BI 1182.52 P. Yeni*1, T. MacGregor2, J. Gathe3, K. Arasteh4, D. Jayaweera5, J. Jemsek6, T. Hawkins7, W. Cameron8, N. Bodsworth9, S. McCallister2, V. Kohlbrenner2, A. Quinson2, J. Leith2, J. Sabo2, D. Mayers2 1Groupe Hosp Bichat-Claude Bernard, Paris, France; 2Boehringer Ingelheim, Ridgefield, CT; 3Houston, TX; 4Epimed GmbH, Berlin, Germany; 5Jackson Med Ctr, Miami, FL; 6Jemsek Clin, Huntersville, NC; 7Southwest CARE Ctr, Santa Fe, NM; 8Ottawa Hosp, Canada; and 9Taylor Square Private Clin, Darlinghurst, Australia |
| 529 | Are Random Antiretroviral Drug Levels Associated with Objectively Measured Adherence Behavior? C. Liechty*1, C. Alexander2, R. Harrigan2, D. Guzman1, E. D. Charlebois1, A. R. Moss1, D. R. Bangsberg1 1Univ of California at San Francisco and 2British Columbia Ctr for Excellence in HIV/AIDS, Vancouver, Canada |
| 530 | Differential Phosphorylation of Zidovudine and Lamivudine Between Semen and Blood Mononuclear Cells in HIV-1 Infected Men S. Reddy*1, L. Troiani1, J. Kim1, J. Rodriguez2, S. Fiscus1, A. V. Kempen3, M. Cohen1, A. Kashuba1 1Univ of North Carolina, Chapel Hill; 2Univ of Puerto Rico; and 3GlaxoSmithKline |
| 531 | Lopinavir/Ritonavir Combined with Twice-daily Indinavir: Pharmacokinetics in Blood, CSF, and Semen (The Protect Study) A. Isaac*1, S. Taylor2, G. Rubin3, S. Gibbon1, D. White1, S. Drake1, D. Back4 1Birmingham Heartlands Hosp, UK; 2Univ of Birmingham, UK; 3Canadian Immunodeficiency Collaborative, Toronto; and 4Univ of Liverpool, UK |
| 532 | Antiretroviral Proficiency Testing Program for the Adult AIDS Clinical Trials Group (AACTG) Pharmacology Laboratory Network D. Holland*1,2, R. DiFrancesco2,3, F. Hamzeh, G. D. Morse 1Univ of California at San Diego; 2Div of AIDS, NIAID, NIH, Bethesda, MD; 3Univ at Buffalo, NY; 4Johns Hopkins Univ, Baltimore, MD; and 5Baltimore, MD |